Fairvalue-Calculator Fairvalue-Calculator

Pulse Biosciences, Inc (PLSE) Fair Value & Analysis

Healthcare · US · Market cap $1.8B

Price$25.95
Fair Value$5.24
Upside-79.8%
Quality95/100
Evidence: Low Range $3.93 – $6.56

Analysis

Pulse Biosciences, Inc (PLSE) currently trades at $25.95, while our model-based Fair Value estimate is $5.24 — implying the stock looks roughly 79.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -61% EssilorLuxottica Société anonyme (ESLOF) -34% HOYA Corporation (HOCPY) -42% Medline Inc (MDLN) -5% Becton, Dickinson and Company (BDX) -16% Alcon Inc (ALC) -44%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.